One patient with metachronous LCH and Hodgkin lymphoma bearing the BRAFV600E mutation has been reported [30] and there is evidence from a case submitted to the workshop (Table 1, case 16) as a mixed LC/non-LC sarcoma—as suggested by the submitter—that has been classified by the panel as LC sarcoma with aberrant expression of CD163. The gene discussed is CD163; the disease is sarcoma.